Related Experiment Video

Updated: Jun 23, 2026

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

15.1K

The cancer-associated SF3B1K700E spliceosome mutation confers enhanced sensitivity to BV-6-induced cytotoxicity

Lydia E Roets1, Jaine K Blayney1, Hayley P McMillan1

  • 1Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.

Cell Death & Disease
|July 2, 2025
PubMed

Insights

The SF3B1K700E mutation in cancer cells reduces cFLIP and affects BCL2 splicing, increasing sensitivity to the drug BV-6. This suggests BV-6 as a potential therapy for SF3B1 mutant cancers.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Genetics

Background:

  • Recurrent somatic mutations in SF3B1, a spliceosome component, occur in various cancers.
  • The SF3B1K700E mutation is common, but its downstream effects on cancer progression and therapy response are not fully understood.

Purpose of the Study:

  • To investigate the impact of the SF3B1K700E mutation on cellular responses to apoptosis-inducing agents.
  • To identify specific molecular changes and therapeutic vulnerabilities associated with SF3B1K700E.

Main Methods:

  • Utilized cell line models to study the SF3B1K700E mutation.
  • Assessed cellular responses to various apoptosis-inducing agents.
  • Analyzed splicing and translation of key apoptosis-related genes.

Main Results:

  • SF3B1K700E mutation leads to decreased cFLIP levels.
  • Observed defects in BCL2 splicing and translation in cells with the mutation.
  • Mutation confers increased sensitivity to the bivalent SMAC mimetic BV-6 due to altered apoptotic balance.

Conclusions:

  • The SF3B1K700E mutation impacts apoptosis regulation by affecting cFLIP and BCL2.
  • BV-6 demonstrates therapeutic potential for cancers harboring SF3B1 mutations.
  • Further research into SF3B1K700E-driven pathways may reveal new therapeutic strategies.

More Related Videos

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.9K
Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors09:22

Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors

Published on: February 28, 2021

5.6K

Related Concept Videos

RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Spontaneous and Induced Mutations01:30

Spontaneous and Induced Mutations

Spontaneous mutations arise infrequently during DNA replication due to errors in the process. A key factor behind these errors is tautomeric shifts in nitrogenous bases, where bases transition from keto to enol forms or amino to imino forms. This shift can alter base-pairing rules, leading to mutations. Additionally, reactive oxygen species (ROS) arising from aerobic metabolism can damage DNA, resulting in depurination (loss of a purine base) or depyrimidination (loss of a pyrimidine base).